Balaglitazone Inhibitor

Name: Balaglitazone Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764521
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764521

Balaglitazone is a selective partial agonist for PPARgamma (EC50: 1.351uM for human PPARgamma). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Balaglitazone, Inhibitor

Full Product Name

Balaglitazone

Product Synonym Names

DRF 2593; NN 2344

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

395.43

Solubility

DMSO: 480mg/mL (1213.87mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C20H17N3O4S

SMILES

O=C1C2=CC=CC=C2N=C(COC3=CC=C(CC4C(NC(S4)=O)=O)C=C3)N1C

CAS Number

199113-98-9

Cell Research

MTT assay is used for cell viability analyses. Briefly, K562 and K562/DOX cells are seeded in a 96-well plate in RPMI-1640 medium supplemented with 10% FBS at the density of 2 x 104cells/well. After 24 hours incubation, various concentrations of doxorubicin (DOX) with or without balaglitazone are diluted in RPMI-1640 medium (without FBS) and added into each well. Experiments for each group are performed in triplicates and with a blank control. After 48 h of treatment, the medium is removed and 200uL of RPMI-1640 medium supplemented with 10% FBS and 10% MTT (5mg/mL) is added. After incubation for another 4 h, the reduced intracellular formazan product is dissolved by replacing 100uL of RPMI-1640 medium with the same volume of dimethyl sulfoxide (DMSO). Absorbance values are measured at 570nM with a microplate reader. The half-maximal inhibitory concentration (IC50) of each experiment is calculated. The resistance fold (RF) is calculated by dividing the IC50 value of treatment,in resistant cells by the IC50 value of treatment,in corresponding parental cells [2].

Product Categories/Family for Balaglitazone, inhibitor

Metabolism; PPAR

Product References and Citations for Balaglitazone, inhibitor

Larsen PJ, et al. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9.
Larsen PJ, et al. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9.
Yousefi B, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARgamma-dependent manner in leukemia cells. Tumour Biol. 2017 Oct;39(10):1010428317716501.
Yousefi B, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARgamma-dependent manner in leukemia cells. Tumour Biol. 2017 Oct;39(10):1010428317716501.
Henriksen K, et al. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):340-5.
Henriksen K, et al. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):340-5.

Other Notes

Small volumes of Balaglitazone, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Balaglitazone purchase

MBS5764521 is an inhibitor targeting Balaglitazone.